Literature DB >> 396282

A comparative study of canine and human breast cancer.

L N Owen.   

Abstract

The incidence of mammary tumours in the bitch is probably three times as great as in women. While many of these tumours are mixed mammary tumours about one-third are carcinomas which resemble human breast carcinomas. Allowing for differences in life span, the age at onset is similar in both species. The World Health Organization classification of tumours and dysplasias of the canine mammary gland follows as far as possible the WHO classification for human breast tumours. Clinical staging of canine mammary tumours has now been completed. Some prognostic factors are similar in both species but regional lymph node metastasis does not seem to be of major importance in the bitch; mitotic activity may also not be as important as in women. Metastatic spread is broadly similar in both species except that involvement of the liver and skeleton is not as common in the bitch as in women. In older normal Beagles hyperplastic and neoplastic nodules commonly appear in the mammary gland, and they occur earlier in animals receiving large doses of progestogens. This has produced problems for the drug industry when conducting long-term carcinogenicity tests on progestogens present in the human contraceptive pill. Despite considerable endocrinological differences between the two species, oophorectomy is sparing for breast cancer in both. As in women, oestrogen and progesterone receptors have been detected in mammary carcinomas in bitches. Canine tumours can be grown in tissue culture but cloned cell lines have not yet been obtained. Transplantation can be made into nude mice and immunosuppressed neonatal dogs. The prognosis following mastectomy for invasive tubular adenocarcinoma and invasive solid carcinoma in the bitch is poor and these histological types make the best models for breast cancer in women. International trials are planned using chemotherapy and/or immunotherapy following mastectomy and, as results can be obtained within 3 years of commencement, it is expected that canine mammary tumours will play an increasingly important role in research which may lead to improved methods of treatment in human breast cancer.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 396282

Source DB:  PubMed          Journal:  Invest Cell Pathol        ISSN: 0146-7611


  30 in total

1.  Histopathologic and dietary prognostic factors for canine mammary carcinoma.

Authors:  F S Shofer; E G Sonnenschein; M H Goldschmidt; L L Laster; L T Glickman
Journal:  Breast Cancer Res Treat       Date:  1989-01       Impact factor: 4.872

2.  Animal models for hormone-dependent human breast cancer. Relationship between steroid receptor profiles in canine and feline mammary tumors and survival rate.

Authors:  P M Martin; M Cotard; J P Mialot; F André; J P Raynaud
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

3.  Intratumoral BCG and Corynebacterium parvum therapy of canine mammary tumours before radical mastectomy.

Authors:  A L Parodi; W Misdorp; J P Mialot; M Mialot; A A Hart; M Hurtrel; J C Salomon
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

4.  Characterization of four in vitro established canine mammary carcinoma and one atypical benign mixed tumor cell lines.

Authors:  E Hellmén
Journal:  In Vitro Cell Dev Biol       Date:  1992-05

5.  Expression and significance of PTEN and VEGF in canine mammary gland tumours.

Authors:  C W Qiu; D G Lin; J Q Wang; C Y Li; G Z Deng
Journal:  Vet Res Commun       Date:  2008-05-07       Impact factor: 2.459

6.  Frequent genetic defects in the p16/INK4A tumor suppressor in canine cell models of breast cancer and melanoma.

Authors:  Farruk M Lutful Kabir; Patricia DeInnocentes; Allison Church Bird; R Curtis Bird
Journal:  In Vitro Cell Dev Biol Anim       Date:  2021-05-20       Impact factor: 2.416

7.  Generation of a canine anti-EGFR (ErbB-1) antibody for passive immunotherapy in dog cancer patients.

Authors:  Josef Singer; Judit Fazekas; Wei Wang; Marlene Weichselbaumer; Miroslawa Matz; Alexander Mader; Willibald Steinfellner; Sarah Meitz; Diana Mechtcheriakova; Yuri Sobanov; Michael Willmann; Thomas Stockner; Edzard Spillner; Renate Kunert; Erika Jensen-Jarolim
Journal:  Mol Cancer Ther       Date:  2014-04-22       Impact factor: 6.261

8.  Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting.

Authors:  Josef Singer; Marlene Weichselbaumer; Thomas Stockner; Diana Mechtcheriakova; Yury Sobanov; Erika Bajna; Friedrich Wrba; Reinhard Horvat; Johann G Thalhammer; Michael Willmann; Erika Jensen-Jarolim
Journal:  Mol Immunol       Date:  2012-04       Impact factor: 4.407

9.  Molecular plasticity of E-cadherin and sialyl lewis x expression, in two comparative models of mammary tumorigenesis.

Authors:  Salomé S Pinho; Celso A Reis; Fátima Gärtner; Mary L Alpaugh
Journal:  PLoS One       Date:  2009-08-13       Impact factor: 3.240

10.  The ESR1 gene is associated with risk for canine mammary tumours.

Authors:  Kaja Sverdrup Borge; Malin Melin; Patricio Rivera; Stein Istre Thoresen; Matthew Thomas Webster; Henrik von Euler; Kerstin Lindblad-Toh; Frode Lingaas
Journal:  BMC Vet Res       Date:  2013-04-10       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.